Ahura Scientific, Inc., the leader in field-deployed analytical instruments for human health and public safety, today announced two milestones: it has reached $100 million in product revenue since its first product shipment in 2005 and the company now serves more than 100 pharmaceutical facilities within two years of introducing its TruScan device to the market.
Ahura Scientific has brought mobility to industries whose solutions were once confined to a laboratory. The company's rapid expansion is based on the need for handheld instruments that can rapidly identify and authenticate chemicals and other substances in the safety and security, pharmaceutical and industrial markets. Innovation in each of these markets has led to broad use of Ahura Scientific instruments worldwide.
“Just as companies transformed the telecommunications industry from landline to wireless and beyond, we are transforming the $40B analytical and life sciences instrument market to provide life-saving information in a mobile format,” said Doug Kahn, chairman and CEO, Ahura Scientific. “We are dedicated to expanding the industries we serve and providing proven science to those in the field.”
Ahura Scientific launched its initial product, FirstDefender, in 2005. The instrument, a rugged handheld Raman spectrometer, enables military personnel and first responders to identify toxic materials, explosives, chemical warfare agents and narcotics. The company later launched TruDefender FT, an FTIR spectrometer that complements FirstDefender for a broader range of chemical identification capabilities.
In 2007, Ahura Scientific applied its expertise to the pharmaceutical market, helping global pharmaceutical manufacturers ensure the safety of their supply chain through raw material verification and anti-counterfeit measures. The company launched TruScan, a handheld instrument that can immediately identify raw materials and finished goods. The instrument can scan through sealed packaging, including bottles or blister packs, without opening them. Currently, nine out of the top 10 pharmaceutical companies (by revenue) have actively deployed TruScan for raw material verification and anti-counterfeit activities.